Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis

Audrey Keller¹, François Lefebvre², Damien Ricard³, Georges Noël¹,⁴, Delphine Antoni¹,⁴

¹Radiotherapy University Department, ICANS, 17, rue Albert Calmette 67200 Strasbourg, France; ²Laboratory of Biostatistics, Faculté de Médecine, 4, rue Kirschleger, 67085 Strasbourg Cedex, France; ³Department of Neurology, Hôpital d’Instruction des Armées Percy, Service de Santé des Armées, 1 Rue du Lieutenant Raoul Batany, 92190 Clamart, France; ⁴Radiobiology Laboratory, EA 3430, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, Strasbourg, France

Contributions: (I) Conception and design: A Keller, G Noël, D Antoni; (II) Administrative support: G Noël; (III) Provision of study materials or patients: A Keller, G Noël, D Antoni; (IV) Collection and assembly of data: A Keller, D Antoni; (V) Data analysis and interpretation: A Keller, F Lefebvre, G Noël, Delphine Antoni; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Prof. Georges Noël, MD, PhD. Radiotherapy University Department, ICANS, 17, rue Albert Calmette, 67200 Strasbourg, France. Email: g.noel@icans.eu.

Background: To assess the risks of local and distant failure and overall survival time in patients treated with hypofractionated stereotactic radiotherapy (HFSRT) to the postoperative cavity for brain metastases (BMs) compared with patients treated with adjuvant whole-brain radiation therapy (WBRT).

Methods: Between July 2005 and February 2015, 196 non-randomized patients with 202 resected BMs were treated with post-operative WBRT or HFSRT at a single institution. The propensity score was included as a covariate to compare the interval to local failure, distant brain failure and overall survival time. The matching covariates consisted of the age, Karnofsky performance status, primary disease, number of BMs, extracranial disease status and presence or absence of extracranial metastases.

Results: In total, 110 patients (54.5%) received adjuvant WBRT, and 92 HFSRT procedures (45.5%) were delivered after surgery. A Cox model adjusted on the propensity score showed that the brain distant failure was significantly associated with treatment modality. Compared with WBRT, the patients who received HFSRT had a significantly greater risk of developing distant brain recurrence [HR =3.37 (2.13–5.33), P<0.001]. No difference was observed in local failure (HR =1.16, P=0.77) between the groups. In the propensity-matched cohort, the effect of treatment on survival was not significant (P=0.14), but it depended on the time. Within the first 20 months, the patients treated with WBRT had a 2 times higher risk of death than did patients treated with HFSRT [HR =2.17 (1.42–3.32), P=0.0003].

Conclusions: Compared with the standard WBRT after the resection of BMs, stereotactic radiotherapy to the surgical bed produced a comparable local control rate to that of WBRT with a survival advantage in the first 20 months.

Keywords: Whole brain radiation therapy; stereotactic radiotherapy; surgical bed; brain metastases (BMs); propensity score

Submitted Dec 17, 2019. Accepted for publication Jun 01, 2020.
doi: 10.21037/cco-19-269
View this article at: http://dx.doi.org/10.21037/cco-19-269
Introduction

Brain metastases (BM) occur in 20% to 30% of all cancer patients (1). Patient’s outcome with BM is generally poor, with median survivals after whole-brain radiation therapy (WBRT) alone in the range of 3 to 6 months (2). Removal of brain metastasis remains the gold standard in several situations. However, surgery only of BM resulted in unacceptably high relapse rates in the surgical bed and/or at new sites in the brain (42%) (3). For two decades, the standard of care for years following the surgical resection of BM has been post-operative WBRT; Patchell et al. described a local and distant disease control advantage for WBRT after the resection of a solitary metastasis, but the trial was not statistically powered and did not show an overall survival (OS) benefit (4). This has gradually led to a new treatment paradigm, namely to perform stereotactic radiotherapy (SRT) of the tumor bed to improve local control with deferring WBRT. A review of 21 retrospective series, including 1,011 patients, showed promising results after such management; the crude one-year control rate in the tumor bed was 79% with 51% of patients developing new BMs (5,6). Additionally, delayed white matter toxicity, detected by magnetic resonance imaging (MRI), occurs more often after WBRT than after SRT, leading to postpone WBRT late (7). A large recent retrospective study of two French centers showed the efficacy and the good tolerance of postoperative fractionated SRT in tumor bed (8). Results of the multi-institutional randomized trial (NCCTG-N107C) was recently published and demonstrated the efficacy of stereotactic radiosurgery (SRS) compared with WBRT in terms of prevention of cognitive side-effects. There was no significant difference in survival, and local control of operated metastases and brain control were worst after stereotactic treatment than after WBRT (9). Furthermore, a second randomized trial showed that stereotactic irradiation of the operative bed was not inferior to WBRT in terms of local relapse but neurological death and overall survival were worst in the stereotactic group compared to the WBRT group (10). Consequently, the impact of postoperative stereotactic irradiation on overall survival remains questioned.

At our single institution, we have previously studied the role of surgery and postoperative WBRT, in which surgical resection followed by WBRT produced a better outcome than did WBRT alone for RPA I or II patients with 1 or 2 BMs (11). In the present report, we compared the clinical outcomes of adjuvant hypofractionated stereotactic radiotherapy (HFSRT) whose results were previously published (8) with those of WBRT after the resection of BMs. To perform a comparative analysis of this non-randomized patient cohort, we used propensity score-based analysis.

We present the following article in accordance with the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/cco-19-269.

Methods

We retrospectively reviewed 202 patient data and radiotherapy procedures (WBRT, n=110; HFSRT, n=92) following the neurosurgical resection of BMs delivered between July 2005 and February 2015. One hundred ninety-six patients with 1–3 metastases and Recursive Partitioning Analysis (RPA) Class I to III were included in our study. In the group surgery followed by HFSRT, patients who had undergone a previous WBRT were excluded from the analysis. Local failure (LF) was defined as new or increased contrast enhancement involving the resection cavity on MRI. Distant brain failure (DBF) was defined as the presence of new enhancing BMs or leptomeningeal disease outside the postoperative cavity.

Radiotherapy

Between July 2005 and January 2011, 110 patients underwent WBRT with different schedules according to the RPA Class, prescribed with a boost to the resection cavity. For RPA I patients, a dose of 40 Gy in 20 fractions of 2 Gy (5 fractions per week) was delivered in the whole brain, with a radiation boost on the operative site at a dose of 16 Gy in 8 fractions of 2 Gy. Another schedule was also used with a dose of 37.5 Gy in 15 fractions of 2.5 Gy, followed by a boost at the metastatic site (10 Gy in 4 fractions of 2.5 Gy). For RPA class II and III patients, a dose of 30 Gy in 10 fractions of 3 Gy was delivered, with a boost of 9 Gy in 3 fractions of 3 Gy. WBRT was performed with 6-MV photons of a linear accelerator, using bilateral parallel fields. The radiation boost on the operative site was delivered with 6 or 25 MV after 3-D treatment planning.

Between February 2012 and February 2015, 86 patients with 92 cavities were treated with stereotactic radiotherapy to the resection cavity of BMs. HFSRT was delivered in 3 fractions of 7.7 Gy every 2 days (i.e., d1-3-5) prescribed to the 70% isodose line. A Novalis Tx™ (Varian Medical
Systems®, Palo Alto, CA, USA) linear accelerator was used in all cases. The clinical target volume (CTV) was designated as the entirety of the resection cavity, including any residual enhancing disease, and the planning target volume (PTV) was defined by an automatic extension of CTV with a 2-mm isotropic margin. Treatments were delivered using dynamic conformal arcs or Volumetric Modulated Arc Therapy (VMAT). HFSRT was planned using the Treatment Planning System (TPS) iPlan® RT Dose (Brainlab® AG, Feldkirchen, Germany) for arc therapy or the Eclipse® System (Varian Medical Systems®, Palo Alto, CA, USA) for VMAT planning.

**Statistical analysis**

The baseline characteristics of patients were assessed using descriptive statistics, including the median and range for continuous variables or frequencies and percentages for categorical variables. The end points of this study were local failure-free survival, distant brain failure-free survival and OS. All intervals were calculated from the date of the end of HFSRT or WBRT. Survival curves were carried out using the Kaplan-Meier method and Cox model.

A Propensity Score (PS), defined as the conditional probability of receiving treatment given individual’s covariates, was used to balance the covariates in the two groups, thereby reducing the biases (12,13). It was used to consider the baseline characteristics of the patients. Thus, the covariates consisted of the age, Karnofsky performance status (KPS), primary disease, number of BMs, status of extracranial disease and presence or absence of extracranial metastases. Cox models for competing risks and survival were performed to compare the two treatments, considering the probability of receiving each treatment with the propensity score. The robustness of fit was checked with the test of Harrell (14), and time-dependent covariates were added when necessary. Sub-group models were also performed to determine the effect of treatment over time. A two-sided P value less than 0.05 was taken as statistically significant. All computations were conducted in R, version 3.2.2.

This monocentric retrospective study complies with the “reference methodology” MR004 adopted by the French Data Protection Authority (CNIL) and patients did not object to the use of their clinical data for the research purpose. Written informed consent was obtained from the patient for publication of this study and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

**Results**

**Baseline characteristics in the entire patient cohort**

The median follow-up time of the entire cohort was 14 months (0–71.6). The median age of the patients was 59.3 years (26.2–82.3), and the male to female ratio was 1.2, with 111 males and 91 females. The RPA class distribution was as follows: RPA I (n=34, 16.8%), RPA II (n=158, 78.2%) and RPA III (n=10, 4.9%). The patient characteristics are summarized in Table 1. In total, 110 patients (54.5 %) received WBRT, and 92 HFSRT procedures (45.5%) in 86 patients were delivered following surgical resection. The mean time from surgery to radiotherapy was 50 days (16–92.9, median 45 days). GPA, number of metastases and extracranial metastases were significantly unfavorable in the HFSRT group compared to the WBRT group (P=0.02, P=0.037 and P=0.03, respectively).

The median OS was 15.3 months (95% CI, 11.7–19.0). At the end of the follow-up period, 59 patients were still alive. The 6-, 12-, and 24-month OS rates for the entire group were 74.1% (71–77.2%), 56.7% (53.2–60.2%) and 35.1% (31.6–38.6%), respectively. Of the 137 patients who died, 44 (32.1%) succumbed to their extra-cranial disease, 40 (29.2%) died of progressive intracranial disease, 24 patients (17.5%) died of other causes and 29 causes of death (21.2%) were unknown (Table 2).

**Results in the entire patient cohort and in the propensity score-matched cohort**

The median follow-up time was 14.5 months (0–71.6) and 12.9 months (0.89–40.5) in the WBRT and HFSRT groups, respectively.

After the combined treatment of surgery plus radiotherapy, 77 (39.3%) developed distant brain failure (DBF). The crude DBF rates were 25.4% of cases in the WBRT group and 55.4 % of the cases in the HFSRT group [HR =3.37 (2.13–5.33), P<0.001] (Figure 1).

After the combined treatment of surgery plus radiotherapy, 21 patients (10.4%) developed local failure (LF) at the surgical site. The crude LF rates were 10% after surgery + WBRT, and 13 % after surgery + HFSRT [HR =1.16 (0.43–3.09), P=0.77] (Figure 2).

The 6-, 12-, and 24-month OS rates for the WBRT group were 73.1% (68.8–77.4%), 58.3% (53.6–63%) and
<table>
<thead>
<tr>
<th>Factors</th>
<th>Total</th>
<th>WBRT</th>
<th>HFSRT</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment, n (%)</td>
<td>202 (100.0)</td>
<td>110 (54.5)</td>
<td>92 (45.5)</td>
<td></td>
</tr>
<tr>
<td>Age (years), median (range)</td>
<td>59.3 (26.2–82.3)</td>
<td>59.1 (38.6–78.8)</td>
<td>60.8 (26.2–82.3)</td>
<td>0.82</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>111 (55.0)</td>
<td>61 (55.4)</td>
<td>50 (54.3)</td>
<td>0.87</td>
</tr>
<tr>
<td>Female</td>
<td>91 (45.0)</td>
<td>49 (44.6)</td>
<td>42 (45.7)</td>
<td></td>
</tr>
<tr>
<td>KPS, median (range)</td>
<td>80% (50–100%)</td>
<td>80% (50–100%)</td>
<td>80% (60–100%)</td>
<td></td>
</tr>
<tr>
<td>&gt;70%, n (%)</td>
<td>166 (82.2)</td>
<td>94 (85.4)</td>
<td>72 (78.3)</td>
<td></td>
</tr>
<tr>
<td>≤70%, n (%)</td>
<td>36 (17.8)</td>
<td>16 (14.6)</td>
<td>20 (21.7)</td>
<td></td>
</tr>
<tr>
<td>RPA class, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.32</td>
</tr>
<tr>
<td>I</td>
<td>34 (16.8)</td>
<td>19 (17.3)</td>
<td>15 (16.3)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>158 (78.2)</td>
<td>88 (80.0)</td>
<td>70 (76.1)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>10 (5)</td>
<td>3 (2.7)</td>
<td>7 (7.6)</td>
<td></td>
</tr>
<tr>
<td>GPA, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>0–1</td>
<td>16 (7.9)</td>
<td>4 (3.6)</td>
<td>12 (13.0)</td>
<td></td>
</tr>
<tr>
<td>1.5–2</td>
<td>71 (35.1)</td>
<td>39 (35.5)</td>
<td>32 (34.8)</td>
<td></td>
</tr>
<tr>
<td>2.5–3</td>
<td>80 (39.6)</td>
<td>42 (38.2)</td>
<td>38 (41.3)</td>
<td></td>
</tr>
<tr>
<td>3.5–4</td>
<td>35 (17.3)</td>
<td>25 (22.7)</td>
<td>10 (10.9)</td>
<td></td>
</tr>
<tr>
<td>DS-GPA, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.23</td>
</tr>
<tr>
<td>0–1</td>
<td>13 (7.2)</td>
<td>5 (5.0)</td>
<td>8 (10.1)</td>
<td></td>
</tr>
<tr>
<td>1.5–2</td>
<td>53 (29.4)</td>
<td>29 (28.7)</td>
<td>24 (30.4)</td>
<td></td>
</tr>
<tr>
<td>2.5–3</td>
<td>63 (35.0)</td>
<td>33 (32.7)</td>
<td>30 (38.0)</td>
<td></td>
</tr>
<tr>
<td>3.5–4</td>
<td>51 (28.3)</td>
<td>34 (33.7)</td>
<td>17 (21.5)</td>
<td></td>
</tr>
<tr>
<td>Primary cancer, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.85</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>105 (52.0)</td>
<td>59 (53.6)</td>
<td>46 (50.0)</td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>18 (8.9)</td>
<td>10 (9.1)</td>
<td>8 (8.7)</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>23 (11.4)</td>
<td>13 (11.8)</td>
<td>10 (10.9)</td>
<td></td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>21 (10.4)</td>
<td>11 (10.0)</td>
<td>10 (10.9)</td>
<td></td>
</tr>
<tr>
<td>GI cancer</td>
<td>19 (9.4)</td>
<td>9 (8.2)</td>
<td>10 (10.9)</td>
<td></td>
</tr>
<tr>
<td>Gynecological cancer</td>
<td>11 (5.4)</td>
<td>6 (5.5)</td>
<td>5 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>5 (2.5)</td>
<td>2 (1.8)</td>
<td>3 (3.3)</td>
<td></td>
</tr>
<tr>
<td>Extracranial metastases, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Yes</td>
<td>106 (52.5)</td>
<td>50 (45.5)</td>
<td>56 (60.9)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>96 (47.5)</td>
<td>60 (54.5)</td>
<td>36 (39.1)</td>
<td></td>
</tr>
<tr>
<td>Controlled systemic disease, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.86</td>
</tr>
<tr>
<td>Yes</td>
<td>104 (51.5)</td>
<td>56 (50.9)</td>
<td>48 (52.2)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>98 (48.5)</td>
<td>54 (49.1)</td>
<td>44 (47.8)</td>
<td></td>
</tr>
<tr>
<td>Number of BM, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.037</td>
</tr>
<tr>
<td>1</td>
<td>151 (74.8)</td>
<td>93 (84.5)</td>
<td>58 (63.0)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>36 (17.8)</td>
<td>13 (11.8)</td>
<td>23 (25.0)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>15 (7.4)</td>
<td>4 (3.6)</td>
<td>11 (12.0)</td>
<td></td>
</tr>
</tbody>
</table>

KPS, Karnofsky performance status; GPA, Graded Prognostic Assessment score; DS-GPA, Diagnosis-Specific GPA.
43.5% (38.6–48.4%), respectively. For the HFSRT group, the 6-, 12-, 24-month OS rates were 76.1% (71.7–80.5%), 55.4% (50.2–60.6%) and 24.8% (20–29.6%), respectively. The Cox model adjusted for the propensity score showed that distant brain failure was significantly associated with treatment modality. In the propensity-matched cohort, the effect of treatment on survival was not significant (P=0.14) (Figure 3A), but it depended on the time. Within the first 20 months, patients treated with adjuvant WBRT had a 2.17 times higher risk of death than patients treated with HFRST [HR =2.17 (1.42–3.32), P=0.0003] (Figure 3B). The causes of death in both groups are summarized in Table 2.

Discussion

Recent data have shown that in patients with a solitary brain metastasis or oligometastatic disease, WBRT plus SRS offers improved intracranial control, but not a survival benefit, compared with SRS alone (3,15,16). Thus, patients with limited BMs can be treated with SRT, with the option of deferring the use of WBRT (17,18). This strategy has been extrapolated to the treatment of patients with resected lesions (5,8,19). A recent phase III trial demonstrated the efficacy of SRS with the same OS and less impact on cognitive function and the quality of life compared with WBRT in a post-operative setting (9).

Local control

In our study, HFSRT to the resection cavity produced rates of local tumor control that were comparable to those of WBRT after the resection of a metastatic tumor, and the Cox model adjusted for the propensity score exhibited no difference in local failure [HR =1.16 (0.43–3.09), P=0.77]
between the groups. This result supports the conclusion that stereotactic radiotherapy to the resection cavity is an effective treatment for the management of resected BMs. Studies have reported 1-year LC rates of 73% to 100% after single-dose adjuvant SRS (20-22). Similar numbers have been reported for multi-fractionated SRS using up to 5 fractions (8,23-25). In the meta-analysis of Gans et al., which included 14 studies of post-operative SRS, the mean crude local control was 83% (5). Similarly, in the recent trial of Mahajan et al., the patients were randomized to either SRS or observation of the surgical cavity. The LC rates were superior in the SRS group versus the observation group (HR = 0.46, 95% CI: 0.25–0.85, P=0.011), with LC rates of 72% vs. 45% at 12 months, respectively (26). In comparison, in the randomized trial of Kocher et al., adjuvant WBRT after surgery was shown to have a 2-year local control rate of 73% (3).

Although adjuvant WBRT may be effective for improving local control (LC), significant neurocognitive deficit and memory dysfunction have been reported (16,27).

Controversy

Controversy surrounds the issue of cognitive and neurologic preservation, specifically regarding the relative benefit and risk of WBRT versus those of focused radiation for patients with a limited number of metastases. Indeed, the potential complication of the cognitive decline after WBRT must be weighed against the risk of developing additional intracranial metastases. In fact, one of the benefits of WBRT is the reduction of the appearance of new intracranial metastases. In our series, patients who received HFSRT after surgery had a significantly greater risk of developing distant brain recurrence [HR = 3.37 (2.13–5.33), P<0.001] than did patients with adjuvant WBRT. Regine et al. described an increasingly significant risk of brain tumor failure after the use of SRS alone, 70% of patients developed symptoms at the time of recurrence, and 59% of them had an associated neurologic deficit (28). In a study by Aoyama et al., 132 patients with 1–4 BMs were randomized between WBRT + SRS and SRS alone. The average duration until deterioration was 16.5 months in the WBRT+SRS group versus 7.6 months in the SRS alone group, with a statistical difference (P=0.05). They concluded that control of the brain tumor was the most important factor for stabilizing neurocognitive function (29). However, stereotactic radiotherapy is repeatable if relapse occurs in another brain area (30), and salvage WBRT remains always possible. Thus, close MRI follow-up is mandatory for detecting and treating small metastases, when the risk of neurocognitive deterioration is low.

Moreover, although adjuvant WBRT may be effective to improve local and distant control, a significant neurocognitive deficit and memory dysfunction have been reported after this strategy approach. The randomized trial conducted by Chang et al. recruited 58 patients and was...
stopped prematurely. In fact, an interim analysis revealed that the deterioration in learning and memory function at 4 months after treatment was significantly more frequent among the patients who received WBRT + SRS than among those who received SRS alone (16). In the study of Brown et al., 213 patients with 1–3 metastases were randomized between SRS alone and SRS + WBRT, and less cognitive deterioration was observed at 3 months in the SRS alone group than in the SRS + WBRT group (P<0.001). Furthermore, the quality of life was higher at 3 months with SRS alone (P=0.001). However, there was no statistically significant difference in the overall survival between the groups (P=0.92) (27).

Finally, the result of the recent multi-institutional trial NCCTG-N107C found comparable survival (P=0.65), less cognitive decline [cognitive deterioration at 6 months: 85.7% after WBRT and 53.8% after SRS (P=0.0006)] and better quality of life following SRS versus whole brain radiotherapy after resection. Thus, post-operative SRS has become the new standard of care for patients with resected BMs (9).

One limitation of our study is that the retrospective

![Graph A](image1.png)

**Figure 3** (A) Overall survival since the treatment (months) (P=0.14); (B) overall survival in the first 20 months, since the treatment (months) (P=0.0003).
nature of the data collection was not allowed to identify exhaustively the clinical and neurocognitive evolution of patients treated with radiation. In our propensity-matched cohort, the effect of treatment on survival was not significant (P=0.14), but it depended on the time. Within the first 20 months, the patients treated with WBRT after surgery had a 2 times higher risk of death than patients treated with adjuvant HFSRT to the surgical bed [HR =2.17 (1.42–3.32), P=0.0003]. Furthermore, this survival benefit was observed, despite an increased risk of relapse in the whole brain after HFSRT alone. Both groups were comparable because patients were matched based on the age, Karnofsky performance status, primary disease, number of BMs, status of extracranial disease and presence or absence of extracranial metastases, the main prognostic factors of OS. Indeed, there are several prognostic indices for patients with BMs: the Radiation Therapy Oncology Group’s (RTOG) Recursive Partitioning Analysis (RPA) by Gaspar et al. (31), Graded Prognostic Assessment (GPA) developed from a database of 1,960 patients (32), and a recent diagnosis-specific prognostic index, the DS-GPA, based on a multi-institutional retrospective analysis of 4,259 other patients with BMs from breast carcinoma, small-cell and non-small cell lung carcinoma, GI cancers, melanoma, and renal cell carcinoma (33). This recent index is the sum of the scores for each of, maximally, four prognostic factors (age, KPS, extracranial metastases and number of BMs), adapted to the histology. Thus, it was important to match our patients on these same prognostic factors.

In our analysis, there was a survival benefit within the first 20 months for patients treated with adjuvant HFSRT. Several explanations could be given for this difference in survival. First, the deaths could be attributed directly to the treatment, specifically WBRT. However, 23% of the patients died of a neurological cause in the WBRT group, as did 36.5% of those in the HFSRT group, but we cannot definitively conclude because many of the patients in the WBRT group died of an unknown cause (35.1% vs. 4.8% in the HFSRT group).

Otherwise, WBRT induced a delay in the delivery of systemic therapy during the weeks of administration of radiotherapy. A longer time without systemic therapy can cause the progression of the primitive tumor or even a seeding of tumor cells, with a potential impact on survival. HFSRT may be particularly important to avoid these delays for patients with newly diagnosed primary tumors or progressing systemic disease.

Another explanation is that several weeks after the administration of WBRT, patients continued to recover from its acute side effects: fatigue, somnolence syndrome, and transient cognitive impairment (34,35). It is possible that other complications occurred during this worsening of the general state. It should also be noted that the populations were comparable at the time of radiation therapy, in terms of Karnofsky Performance Status (median KPS 80%) or DS-GPA score (P=0.23). Moreover, the Graded Prognostic Assessment (GPA) was slightly better in the WBRT group than in the HFSRT group (P=0.02). Thus, patients treated with WBRT did not have a worse prognosis than patients treated with HFSRT, which cannot explain the differential survival rate.

Finally, and maybe a bias in our study, the two groups of patients were treated in two different periods (between 2005 and 2011 for WBRT and from 2012 to 2015 for HFSRT). The systemic therapies, which were not considered in our analysis, were probably different. In fact, the targeted therapies that are now transforming the treatment of cancer have changed the chances for some cancer patients drastically. Progress has been achieved, particularly in the treatment of lung cancer, which is the most represented population in our study (52%) (36).

However, in this context of increased control of systemic disease, patients had a higher risk to develop brain recurrences and had a potentially higher risk to die from their intracranial disease, particularly in the HFSRT group, in which the risk of developing intracranial metastases is more important. Thereby, caution is still advised.

**Propensity score**

Propensity score matching is a robust method that attempts to estimate the effect of a treatment by accounting for the covariates that predict receiving the treatment to reduce the bias due to confounding variables. For retrospective studies, the assignment of each treatment is not possible, and propensity score matching attempts to mimic randomization. Evidence-based medicine depends on well-designed and conducted research, but patients are often included according to very specific criteria, and these selected populations do not always reflect reality. Furthermore, the inclusion in a randomized trial can be long, and the technical progress and innovations seem to proceed ahead of the clinical trial initiatives. Indeed, evidence-based medicine can be surpassed by the evolution of technology, so the new treatment can take the place of the standard of care, without proof of a trial. To gain speed (evidence-based
care is increasingly complex and rapidly changing) and power (a small population limits the ability to test research hypotheses with sufficient power to draw conclusions), the experience at a single center level could increase with the development of big data (37,38).

Conclusions

Stereotactic radiotherapy to the resection cavity is an effective treatment in the management of resected BMs, with comparable local control rates of adjuvant whole-brain radiotherapy. Unsurprisingly, patients who received focused therapy in the surgical bed had a significantly greater risk of developing distant brain recurrence than patients treated with WBRT. However, this increased risk did not affect patient survival. By contrast, a survival advantage was observed in the HFSRT group in first 20 months. The use of the propensity score has brought a statistical power of this retrospective series.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/cco-19-269

Data Sharing Statement: Available at http://dx.doi.org/10.21037/cco-19-269

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cco-19-269). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The trial was conducted in accordance with the Declaration of Helsinki. This monocentric retrospective study complies with the “reference methodology” MR004 adopted by the French Data Protection Authority (CNIL) and patients did not object to the use of their clinical data for the research purpose. Written informed consent was obtained from the patient for publication of this study and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References